Merck Sharp & Dohme Corp. v. Lupin Ltd. et al.

I'll research this case across dockets, opinions, and industry sources.

Let me dig into the specific Lupin docket, the settlement, and the parallel IPRs.

Let me pin down the Lupin-specific settlement and the IPR/ Federal Circuit outcomes.

Case Overview — Merck Sharp & Dohme Corp. v. Lupin Ltd., No. 1:19-cv-00347-RGA (D. Del.)

Parties and their roles. This is a classic Hatch-Waxman brand-versus-generic action, not an NPE/PAE suit. Plaintiff Merck Sharp & Dohme Corp. (now Merck Sharp & Dohme LLC) is a wholly owned subsidiary of Merck & Co., Inc. and the operating-company innovator that markets JANUVIA (sitagliptin phosphate), JANUMET (sitagliptin phosphate + metformin HCl) and JANUMET XR; Merck is the assignee/patent owner of the '708 patent. Defendants Lupin Ltd. (Mumbai, India) and its U.S. affiliate Lupin Pharmaceuticals, Inc. are generic manufacturers that filed Abbreviated New Drug Application(s) with a Paragraph IV certification seeking FDA approval for generic sitagliptin phosphate products before the '708 patent expires. Merck's theory is the standard § 271(e)(2)(A) constructive-infringement theory — that the ANDA filing itself is an act of infringement — coupled with induced/contributory infringement and a declaratory-judgment count.

Accused product, patent, and posture. The accused technology is Lupin's proposed generic sitagliptin phosphate drug product(s) — i.e., generic versions of JANUVIA and/or JANUMET. (I could not verify from public sources in this session the specific Lupin ANDA number(s) or exactly which of the three brand products its ANDA mirrored; the MDL record shows Merck filed against 26 ANDAs covering Januvia, Janumet and Janumet XR generally.) The sole patent at issue, U.S. Patent No. 7,326,708, "Phosphoric Acid Salt of a Dipeptidyl Peptidase-IV Inhibitor," issued Feb. 5, 2008, lists Cypes, Chen, Ferlita, Hansen, Lee, Vydra and Wenslow as inventors with Merck as assignee. Technically, the '708 patent claims the 1:1 dihydrogenphosphate ("DHP") salt of sitagliptin (sitagliptin phosphate), the (R)-enantiomer, and the crystalline monohydrate thereof, plus pharmaceutical-composition, method-of-treating-Type-2-diabetes, and process claims — a compound/salt-and-polymorph patent layered on top of Merck's earlier, now-expired sitagliptin compound patent. It expires Nov. 24, 2026, with pediatric exclusivity to May 24, 2027 per Merck and the Orange Book. Filed in the District of Delaware and assigned to Judge Richard G. Andrews, the case was swept into MDL No. 2902, In re Sitagliptin Phosphate ('708 & '921) Patent Litigation by a J.P.M.L. transfer order signed Aug. 8, 2019 (Dkt. 56, MDL 2902, Judge Sarah S. Vance chairing; Judge Andrews as transferee). Delaware mattered because 13 of the 14 original actions were already pending there, and the Panel expressly credited Judge Andrews's experience with complex patent litigation; the MDL consolidated pretrial proceedings only, so the Lupin case retained its own -RGA docket number. Delaware is also a favored ANDA forum generally (many generics are incorporated there, and its bench is highly experienced and fast in Hatch-Waxman cases). The Lupin case was actively litigated into late 2020 (Markman argument ordered for Aug. 18, 2020, with the court directing that the '921-related terms "surfactant" and "sitagliptin" be argued first and the '708 terms after; extensive joint discovery and Rule 30(b)(6) depositions), and the metadata indicates it ultimately settled. I could not verify the precise dismissal date or settlement terms in this session.

Why it's notable. The case is one piece of the largest pharmaceutical patent consolidation of its era: 23 defendants in 13 corporate groups, 26 ANDAs, and the only significant consolidation of an entire blockbuster franchise in Delaware — protecting a business then producing roughly $2.25B (Januvia) plus ~$1.43B (Janumet/Janumet XR) in annual U.S. sales. It is equally notable for its IPR linkage: Mylan's IPR2020-00040 (filed Oct. 30, 2019, instituted May 12, 2020) challenged claims 1–4, 17, 19 and 21–23 of the '708 patent, and Teva/Watson (IPR2020-01045), Dr. Reddy's (IPR2020-01060) and Sun (IPR2020-01072) filed substantively identical "me-too" petitions that were joined to the Mylan IPR in a "silent understudy" role — an enduring example of post-SAS joinder strategy in a multi-defendant ANDA MDL. The Board's Final Written Decision of May 7, 2021 held no challenged claims unpatentable, rejecting the inherency/anticipation attack based on Merck's own WO 03/004498 and the '871 patent; Mylan, DRL and Sun noticed appeals in July 2021 (appellate outcome not verified here). Separately, the first case tried — Merck v. Mylan/Viatris in N.D. W. Va. before Judge Irene Keeley — ruled for Merck on Sept. 22, 2022, upholding validity and infringement of both the '708 and '921 patents. Merck subsequently settled with 25+ generics (including, per the case metadata, Lupin) on terms allowing generic JANUVIA/JANUMET entry in May 2026 and JANUMET XR in **July

I'll research this case thoroughly. Let me start with several searches.

Let me get the specific docket for this case and details on key events.

I'll research press coverage of this case, starting with the cited IPWatchdog roundup and broader searches.

Let me dig into whether the IPWatchdog roundup mentions this case, and search targeted outlets.

Let me check whether the IPWatchdog roundup actually discusses this case, and search for other outlets.

Press and trade coverage of Merck v. Lupin

Case-specific coverage is thin, and I want to be candid about that up front. This docket was one of roughly fourteen member actions folded into MDL No. 2902, and the trade press covered the sitagliptin litigation at the franchise level (the IPRs, the N.D. W. Va. trial, the launch-date settlements) rather than tracking 19-cv-00347 individually. The clearest contemporaneous record of the filing is the Robins Kaplan Generically Speaking Hatch-Waxman bulletin (Spring 2019 new-ANDA-cases table), which lists Merck Sharp & Dohme Corp. v. Lupin Ltd., No. 19-0347 (D. Del.), before Judge Richard G. Andrews, as a Janumet (sitagliptin phosphate / metformin HCl) case asserting only U.S. Patent 7,326,708. The practitioner tracking site Paragraph IV Disputes/paragraphfour.com similarly records the Lupin action as "Janumet® (sitagliptin and metformin) Tablets," with Bruce Genderson of Williams & Connolly as plaintiff's counsel and the '708 patent expiring 11/24/2026 — and separately notes a companion Lupin action, No. 1:20-cv-00776 (covering two ANDAs including Januvia), in which a "Consent Judgment enter[ed] 3/11/21." That last data point is worth flagging: it suggests at least part of the Lupin dispute resolved by consent judgment in March 2021, which is consistent with, but does not precisely confirm, the "settled" status in the case metadata. I found no reported damages figure, no disclosed Lupin-specific settlement terms, and no article naming Lupin among the settling generics in so many words.

The substantive press coverage treats the '708 patent as one front in a franchise-wide fight, not as a Lupin story. pharmaphorum reported that the Federal Circuit upheld the PTAB's May 2021 decision sustaining the '708 patent against Mylan/Viatris's IPR challenge — a "second victory in quick succession" after Merck's win in the N.D. W. Va. district court case the prior week on the '708 and '921 patents — and noted the '708's November 2026 expiry, Januvia's roughly $2.5 billion in first-half-2022 sales, and that Merck "has previously reached settlement agreements with more than 20 other generics companies that have deferred their launch plans for generics until May or July 2026 depending on the formulation, 'or earlier under certain circumstances.'" Williams & Connolly's own firm announcement frames the same arc from the plaintiff side, noting that the September 22, 2022 bench-trial win "followed a settlement on the eve of trial of related matters that had been coordinated as an MDL proceeding in the District of Delaware" — i.e., the MDL of which this Lupin case was a part — and that the team was named an American Lawyer "Litigator of the Week Runner Up" for the IPR and trial wins. Later commentary, such as DrugPatentWatch, uses the franchise as a case study in the gap between listed expiry (May 24, 2027 with pediatric exclusivity) and settlement-adjusted entry (May 2026 for Januvia/Janumet, July 2026 for Janumet XR), reporting subsequent generic launches by Sandoz (May 26, 2026) and Apotex (June 2, 2026) — while a Robins Kaplan generic-launch chart instead lists Teva at 5/27/2026 and Apotex at 5/28/2026, a discrepancy among the trackers I could not resolve.

On the specific IPWatchdog article supplied for this section: I retrieved the piece — "Patent Filings Roundup: End-of-Month Filing Spike; IP Val Sues Smart Thermostat Cos.," by Jonathan Stroud, IPWatchdog, dated February 11, 2022 — and I want to be precise rather than assume. The accessible text covers IP Valuation Partners' Rosen Technologies thermostat campaign in W.D. Tex. (Judge Albright), the seven asserted "space conditioning equipment" patents, IPVal's principals, and counsel Ni, Wang & Massaud. I found no reference in the retrievable text to Merck, Lupin, sitagliptin, Januvia/Janumet, the '708 patent, or MDL 2902. Since I could not load the article's full text (roundups of this type typically carry PTAB and district-court filing tables below the prose), it is possible the case appears there in tabular form, but I will not assert that it does. If this article was included on the theory that it reports on this case, that premise did not check out on the text I could access.

Bottom line on the press record: the docket's significance is documented almost entirely at the franchise level — the '708 IPR/Federal Circuit affirmance, the N.D. W. Va. validity win, and the 2026 settlement-based entry dates — and no outlet I found reported Lupin-specific terms, a Lupin-specific outcome date, or any Lupin executive statement. Any account stating what Lupin specifically agreed to, or a precise dismissal date for 19-cv-00347, would need the docket sheet itself; I could not source either from the press.

Sources

• ANDA Litigation Settlements
• Merck defends blockbuster Januvia franchise from patent challenge
• Janumet ((\widehat{\Xi})) (sitagliptin phosphate / metformin HCl) 7,326,708 Merck Sharp & Dohme Corp
• UNITED STATES JUDICIAL PANEL on MULTIDISTRICT LITIGATION
• Generic Launches
• As previously disclosed, beginning in 2019, a number of generic drug companies filed ANDAs seeking approval of generic forms of ...
• Worldwide combined sales of Januvia and Janumet, medicines that help lower blood sugar levels in adults with type 2 diabetes, de...
• Ro vs. Hims & Hers: What the Compounding Crackdown Actually Did - Merck’s core sitagliptin compound patent expired in 2023. A separate patent covering the dihydrogen phosphate salt and polymorph...
• シタグリプチンに関する特許権侵害訴訟が当社の請求を沢井製薬らが全面的に認める形で終了 | MSD
• Patent Filings Roundup: End-of-Month Filing Spike; IP Val Sues Smart Thermostat Cos. - Patent Filings Roundup: End-of-Month Filing Spike; IP Val Sues Smart Thermostat Cos.
• Muck Rack | For journalists and public relations - Is this you
• Merck Sharp & Dohme Corp

I'll research the docket and related filings for plaintiff's counsel in this case.

Good leads emerging. Let me dig into the specific docket and Delaware counsel.

Strong evidence accumulating. Let me verify the specific 19-cv-347 docket and the appearances filed in that case.

I hit my research-step limit while trying to pull the individual 19-cv-347 docket sheet directly. Here is what the record I could retrieve establishes — with sourcing caveats flagged.

Counsel of Record for Plaintiff Merck Sharp & Dohme Corp.

Important sourcing note up front: Case No. 1:19-cv-00347-RGA is a member case of MDL No. 19-2902-RGA (In re Sitagliptin Phosphate ('708 & '921) Patent Litigation), consolidated before Judge Richard G. Andrews in D. Del. I was not able to open the standalone 19-cv-347 docket sheet/PACER attorney list directly. The roster below is drawn from (a) the consolidated MDL docket sheet for 19-md-2902-RGA, (b) the MDL § 1407 motion that Merck filed (which names 19-cv-347 among the actions to be centralized), (c) the MDL claim-construction opinion listing "attorneys for Plaintiff," and (d) Merck's PTAB mandatory notices in the parallel '708 IPRs. Because these attorneys represented Merck across the consolidated sitagliptin litigation and the '708 IPRs, they are the operative plaintiff's team for this case; individual appearances in 19-cv-347 specifically are inferred from the multi-case pro hac vice orders, noted below.

Delaware / Local Counsel — McCarter & English, LLP (Wilmington, DE)

All three signed Merck's MDL No. 2902 § 1407 motion (Doc. 1-1, filed May 15, 2019) as "Attorneys for Plaintiff Merck Sharp & Dohme Corp.," which is the filing that swept 19-cv-347 into the MDL.

Lead / National Trial Counsel — Williams & Connolly LLP (Washington, D.C.)

Additional pro hac vice appearances (case-specific, lower confidence)

A Unified Patents litigation page for the related Delaware sitagliptin actions shows pro hac vice motions "filed by Merck Sharp & Dohme Corp." that expressly reference 19-cv-347-RGA as one of the member dockets:

• Jeffrey Ho — pro hac vice appearance granted by Judge Andrews on Jan. 25, 2021 (order cites docket entry "142 in 19-cv-347-RGA").
• Vanessa O. Omoroghomwan — pro hac vice appearance granted June 24, 2021 (order cites "123 in 19-cv-347-RGA").
• A September 28, 2020 pro hac vice order (covering Genderson, Berniker, Fisher, Zolan, Baumgarten and Mahaffey) is docketed across the member cases, consistent with the W&C team entering 19-cv-347.

I could not independently confirm these attorneys' individual firms from a primary filing, so treat Ho's and Omoroghomwan's firm affiliations as unverified (they are commonly associated with Williams & Connolly's Merck sitagliptin team, but I did not verify that here). The plaintiff's-side signatory "Silver, Daniel" appears repeatedly as the ECF filer of Merck's substantive papers (answers to counterclaims, infringement contentions, discovery responses) in the sitagliptin MDL docket, which is consistent with McCarter & English acting as Delaware counsel.

What I did not find

• No in-house Merck attorney appears of record in this matter on the sources I could reach. Merck used outside counsel (Williams & Connolly + McCarter & English) throughout the sitagliptin MDL.
• I found no sealed or withdrawn appearances specific to 19-cv-347, but I could not open the case's docket sheet directly, so I cannot rule out later substitutions or withdrawals (e.g., the case is recorded as settled, and post-settlement filings may list a narrower team).

Consistency check

This roster is consistent with the "In the news" section already generated: the PTAB documents cited there (IPR2020-00040 mandatory notices) list Stanley E. Fisher as Merck's lead counsel with Berniker, Genderson, Krinsky, Zolan, and Baumgarten as backup, and list Merck Sharp & Dohme Corp. v. Lupin Limited and Lupin Pharmaceuticals, Inc., No. 1:19-cv-00347-RGA (D. Del.) as a related litigation — i.e., the same team litigated the district court case and the '708 IPRs. No contradiction with the case metadata.

Primary sources:

• Docket sheet, In re Sitagliptin Phosphate ('708 & '921) Patent Litig., MDL No. 19-2902-RGA (D. Del.) (attorney listing: Kelly — "LEAD ATTORNEY"; Silver; Joyce; Fisher, Genderson, Berniker, Zolan, Baumgarten, Mahaffey, Sheh as pro hac vice) — via PTAB exhibit at ptacts.uspto.gov.
• MDL No. 2902 Doc. 1-1 (May 15, 2019) (Merck § 1407 motion signed by Kelly, Silver, Joyce of McCarter & English).
• In re Sitagliptin Phosphate ('708 & '921) Patent Litig., MDL No. 19-2902-RGA, D.I. 310 (D. Del. Nov. 17, 2020) (Markman opinion; counsel listing for Plaintiff).
• Patent Owner's Second/Fourth Amended Mandatory Notices, Mylan Pharms. Inc. v. Merck Sharp & Dohme Corp., IPR2020-00040 (PTAB) (Fisher lead; Berniker first backup; Genderson, Krinsky, Zolan, Baumgarten backup).
• Merck Sharp & Dohme Corp. v. Anchen Pharms., Inc., No. 1:19-cv-00311-RGA, D.I. 135 (D. Del. Nov. 17, 2020) (via Justia/CourtListener) ("Daniel M. Silver, Alexandra M. Joyce, McCarter & English LLP,

I'll research the docket and counsel appearances for this case.

Let me dig into the docket sheet and specific counsel appearances.

Found Delaware local counsel. Now let me find Lupin's national/lead counsel in this MDL.

Let me verify the signature block on Lupin's answer/counterclaims and confirm the Knobbe Martens team.